Combipatch and Climara Pro in Women 65 and Older: What the Transition to Adult Care Actually Means for You

What "Transition to Adult Care" Means When You Are Already 65

By the time a woman reaches 65, she has almost certainly been in menopause for more than a decade. The phrase "transition to adult care" in the context of hormone therapy does not describe a pediatric handoff. It describes the often-disorganized clinical moment when ongoing hormonal management moves between providers, whether from a reproductive endocrinologist to a primary care physician, from a menopause specialist to a new practice after relocation, or from a dedicated OB-GYN to a geriatrician as health complexity grows.

That handoff is frequently where continuity breaks down. A 2022 survey-based analysis published in Menopause found that fewer than 20 percent of primary care physicians felt confident managing menopause pharmacotherapy, even when inheriting an established patient on hormone therapy. For you, that gap is not abstract. It can mean an abrupt, unplanned discontinuation of a patch you have used safely for years, or conversely, a continuation without any risk reassessment that should have happened at 65.

This article gives you the clinical specifics you need to walk into that transition prepared.

How Combipatch and Climara Pro Work, and Why the Progestogen Component Matters

Both patches deliver estradiol transdermally alongside a progestogen. Estradiol alone in a woman with an intact uterus causes unopposed endometrial stimulation, raising the risk of endometrial hyperplasia and carcinoma. Adding a progestogen counteracts that effect.

The Two Patch Formulations Side by Side

Combipatch delivers estradiol 0.05 mg and norethindrone acetate 0.14 mg per day, applied twice weekly. Climara Pro delivers estradiol 0.045 mg and levonorgestrel 0.015 mg per day, applied once weekly.

Norethindrone acetate (in Combipatch) is a 19-nortestosterone-derived progestogen with some androgenic activity. Levonorgestrel (in Climara Pro) is also a 19-nortestosterone derivative. Both have higher androgenic potency than progesterone-derived progestogens such as medroxyprogesterone acetate. In older women who are already navigating lipid changes, that androgenic activity is clinically relevant because both progestogens may partially attenuate the favorable HDL effect of estradiol.

Transdermal Delivery and Why It Matters After 65

Oral estrogen undergoes first-pass hepatic metabolism, increasing coagulation factors, C-reactive protein, and triglycerides. Transdermal delivery bypasses that first pass. The ESTHER study found that oral, but not transdermal, estrogen was associated with an elevated risk of venous thromboembolism (VTE). For women 65 and older, whose baseline VTE and cardiovascular risk is already higher than in younger postmenopausal women, the transdermal route carries a meaningful practical advantage over oral preparations, even though the combination patches have not themselves been shown in randomized trials to be VTE-neutral.

The WHI Data You Actually Need to Know at 65

The Women's Health Initiative (WHI) is the largest randomized trial of postmenopausal hormone therapy and it remains the foundational safety reference, even with its well-documented limitations. The WHI used conjugated equine estrogen plus medroxyprogesterone acetate (CEE/MPA), not estradiol-based combination patches. Extrapolating its findings to Combipatch or Climara Pro is therefore indirect, and you should know that.

Breast Cancer

The WHI combination arm showed a hazard ratio of 1.26 for invasive breast cancer in women assigned to CEE/MPA after approximately 5.6 years of use. The 2020 long-term follow-up published in JAMA confirmed persistently elevated breast cancer incidence and mortality in the combination group. Because your risk of breast cancer rises with age regardless of hormone therapy, reassessing the benefit-risk balance at 65 is not optional. The 2022 Menopause Society position statement states that the risk of breast cancer with combination estrogen-progestogen therapy is a function of the progestogen component and duration of use, and that risk increases beyond 3 to 5 years of combined therapy.

Cardiovascular Disease

The WHI showed increased coronary heart disease events in older women initiating combination therapy 10 or more years after menopause. Women 65 and older who have been on therapy continuously since their early 50s are in a different biological position than women starting de novo at 65, but the distinction is not yet validated by large randomized data. The Menopause Society 2022 position statement does not recommend initiating combination systemic hormone therapy after 60 or more than 10 years from menopause primarily for cardiovascular benefit.

Cognitive Health

The WHI Memory Study (WHIMS) found that combined CEE/MPA in women 65 and older was associated with a doubling of dementia incidence compared with placebo. This is one of the clearest age-dependent risk signals in all of hormone therapy research. Whether estradiol-based patches carry the same signal is not known. Direct randomized data in this patient population using transdermal estradiol-progestogen combination therapy are sparse, and this evidence gap should be named plainly: the safety profile of Combipatch and Climara Pro in women 65 and older is partly inferred from the WHI, not established by dedicated trials of these specific formulations.

Sex-Specific Pharmacology After 65: How Aging Changes the Drug

Aging alters how you absorb, distribute, metabolize, and clear any drug. For combination hormone patches in women 65 and older, four changes matter most.

Skin Absorption

Transdermal drug absorption depends on skin hydration, thickness, and perfusion. Older skin is thinner and less hydrated, which can reduce delivery consistency. Application site rotation and ensuring full patch adhesion (particularly during summer heat or excessive sweating) become more operationally important after 65. No large PK study has compared patch absorption directly between 50-year-old and 70-year-old women, so the clinical instruction to check serum estradiol levels periodically if symptom control is inconsistent is practical rather than protocol-driven.

Hepatic and Renal Clearance

Hepatic blood flow and cytochrome P450 activity both decline with age. Estradiol is metabolized primarily by CYP3A4. Slower hepatic clearance means a given transdermal dose may produce higher steady-state estradiol levels in a 70-year-old than in a 50-year-old, even with identical patch delivery. No dedicated PK study has quantified this interaction for Combipatch or Climara Pro specifically.

SHBG and Free Hormone Fraction

Sex hormone-binding globulin (SHBG) levels change with aging, comorbidities, and concurrent medications. Women with hypothyroidism (common after 65) on levothyroxine may have altered SHBG, changing the free-estradiol fraction. This is another reason that monitoring by serum levels rather than relying solely on symptom reports is reasonable in complex older patients.

Drug Interactions in Polypharmacy

Women 65 and older take an average of 5.8 prescription medications. CYP3A4 inducers (rifampicin, carbamazepine, some antiretrovirals) reduce estradiol exposure. CYP3A4 inhibitors (ketoconazole, some macrolides) may increase it. Thyroid replacement, anticoagulants, and antihypertensives all have interactions worth reviewing systematically at every care transition.

Pregnancy, Lactation, and Contraception: A Required Section

Pregnancy. Women 65 and older are post-menopausal and do not become pregnant. Both Combipatch and Climara Pro are contraindicated in pregnancy due to fetal risk from both the estrogen and progestogen components. This section is included because it is a required safety element for any drug article on this platform, and because some younger perimenopausal women on combination patches need to know: if pregnancy is possible, combination hormone patches are not appropriate, and reliable contraception must be used alongside any hormone therapy initiated before confirmed menopause. Progestogen-based hormone therapy does not provide reliable contraceptive protection.

Lactation. Not applicable in women 65 and older. Estrogen-containing products suppress lactation and are not used in breastfeeding women; levonorgestrel and norethindrone acetate transfer into breast milk in small quantities, but this is not a clinical consideration in the geriatric population.

Perimenopause note for completeness. A woman who is 48 and uses Combipatch off-label for perimenopausal symptoms, who then transitions care to a new provider at 51, is in a different position. She may still be capable of pregnancy and needs counseling that hormone therapy in perimenopause does not prevent ovulation reliably.

Who This Is Right For, and Who It Is Not Right For, by Life Stage

The following framework is intended as a clinical decision-support tool for women navigating a care transition at or after 65. It organizes benefit-risk reasoning by the most common clinical scenarios, not by a single age cutoff.

Women Who May Continue Combination Patch Therapy After 65

• Women who started combination patch therapy before 60 and have tolerated it well, have no new cardiovascular risk factors, no breast abnormality on screening, and continue to have bothersome vasomotor symptoms that return with every attempted taper.
• Women with established osteopenia or osteoporosis who have not tolerated or responded to bisphosphonates or other non-hormonal bone agents, where the patch is providing meaningful bone protection alongside symptom relief.
• Women in whom the alternative to continuing a patch is severe genitourinary syndrome of menopause (GSM) that does not respond adequately to vaginal estrogen alone.

Women for Whom Continuation Requires a Careful Conversation

• Women 65 to 70 with newly identified cardiovascular risk factors, including hypertension, dyslipidemia, or diabetes, since the risk-benefit ratio changes when baseline cardiovascular risk rises.
• Women who have used combination estrogen-progestogen therapy for more than 5 years, where cumulative breast cancer risk has increased according to WHI long-term follow-up data.
• Women with a first-degree family history of breast cancer who were not previously counseled specifically about this risk in the context of long-term combination therapy.

Women for Whom Combination Patches Are Generally Inappropriate After 65

• Women with a personal history of estrogen receptor-positive breast cancer. This is a ACOG-supported contraindication.
• Women with active or recent venous thromboembolism, active liver disease, or unexplained vaginal bleeding.
• Women seeking hormone therapy primarily for cognitive protection or cardiovascular disease prevention, since there is no current evidence to support that use in the 65-plus age group and some evidence of harm.

Dose Considerations in the 65-Plus Population

The FDA-approved prescribing information for Combipatch and Climara Pro do not include geriatric-specific dose recommendations, because neither drug was studied in dedicated geriatric trials. Clinical practice, supported by the Menopause Society 2022 position statement, supports using the lowest effective dose for the shortest duration consistent with treatment goals.

In practical terms:

• If a woman has been on the full Combipatch dose (0.05/0.14 mg/day) for 10 years, a trial taper to a lower-dose sequential or lower-dose continuous patch is a reasonable first step at the 65-plus transition, rather than abrupt discontinuation.
• Climara Pro comes in a single dose strength; switching to a lower-dose estradiol-only patch plus separate low-dose progestogen may give more flexibility for dose reduction in women with an intact uterus.
• Abrupt discontinuation of long-standing combination therapy in a woman who is still symptomatic is not the automatic default. The Menopause Society explicitly states that arbitrary age cutoffs for stopping hormone therapy are not evidence-based.

The Annual Reassessment That Has to Actually Happen

At every care transition, and at least once per year in any woman 65 or older on combination hormone therapy, the following should be documented:

Symptom Burden Reassessment

Ask directly. Many older women stop reporting vasomotor symptoms not because they have resolved but because they feel embarrassed discussing them with a new provider. A validated tool such as the Menopause Rating Scale takes under three minutes to complete and gives you and your provider a reproducible score over time.

Cancer Screening Currency

Mammography should be current before continuing combination therapy. Women 65 and older should follow USPSTF guidelines, which as of 2024 recommend biennial mammography through age 74. Beyond 74, the decision is individualized. Cervical cancer screening (Pap/HPV) ends at 65 for most women with adequate prior negative screening per USPSTF cervical cancer guidelines, but endometrial surveillance is not routine for asymptomatic women on combination therapy with adequate progestogen coverage.

Cardiovascular and Metabolic Review

Blood pressure, fasting glucose, lipid panel. The androgenic progestogens in both Combipatch and Climara Pro may attenuate estradiol's favorable effect on HDL cholesterol. A lipid panel at baseline and then every 2 to 3 years, or after any significant dose change, is reasonable.

Bone Density

DXA scanning is recommended every 2 years in women 65 and older per USPSTF, regardless of hormone use. If a woman is discontinuing her combination patch primarily for safety reasons, a plan for alternative osteoporosis management, whether a bisphosphonate, denosumab, or SERM, needs to be in place before the patch is stopped, not after.

Managing the Actual Care Transition: A Practical Guide

The transition itself, not just the therapy, needs active management. Here is what works.

Before the Transition Appointment

Request a complete medication reconciliation that includes the patch. Many electronic health record systems do not capture transdermal medications consistently, and the patch is frequently dropped from the active medication list during a practice merger or EHR migration. Arrive with the brand name, dose, and start year written down.

What to Ask the New Provider

Ask specifically whether they are comfortable managing postmenopausal hormone therapy. If they are not, ask for a referral to a clinician who holds a NAMS Certified Menopause Practitioner (NCMP) credential or equivalent. The Menopause Society maintains a searchable directory of certified practitioners.

If Your New Provider Wants to Discontinue

Ask whether discontinuation is based on a specific risk finding or on a general reluctance to prescribe hormone therapy after 65. These are not the same clinical situation. Ask about a gradual taper plan. Ask what they recommend for your symptoms or bone health if the patch stops. A new provider's discomfort with prescribing is not, by itself, a clinical reason for you to stop a therapy that has been safe and effective for you.

As WomanRx reviewer Rachel Goldberg, MD, notes: "The 65 birthday does not reset the risk-benefit calculation for hormone therapy. What matters is cumulative duration of use, current health status, what symptoms or risks the therapy is addressing, and whether the woman herself understands the trade-offs well enough to make a real choice. Handing that decision to a new provider who hasn't met the patient before is the point of highest vulnerability in her care."

Conditions That Intersect With Combination Patch Use After 65

Several conditions common in women 65 and older interact directly with combination patch therapy.

Osteoporosis. Both Combipatch and Climara Pro maintain bone mineral density. The MORE trial demonstrated that raloxifene reduced vertebral fracture risk in postmenopausal women, offering an alternative that also reduces breast cancer risk, though it does not address vasomotor symptoms. This matters if you are continuing the patch primarily for bone health after your symptoms have resolved.

Hypothyroidism. Common in women 65 and older. Oral estrogen increases thyroid-binding globulin, requiring levothyroxine dose adjustment. Transdermal estradiol has a smaller effect on TBG, which is another advantage of the patch route in women on thyroid replacement.

Urinary incontinence and GSM. Systemic estradiol improves genitourinary syndrome of menopause symptoms including dyspareunia and recurrent UTIs. However, systemic hormone therapy alone is not considered adequate treatment for stress urinary incontinence and may worsen it in some women. Vaginal estrogen used alongside a systemic patch is safe and provides additional local benefit.

Female pattern hair loss. Norethindrone acetate's androgenic activity may worsen androgenic alopecia in susceptible women. If new or worsening hair loss develops on Combipatch, consider switching to a less androgenic progestogen formulation after discussion with your provider.

What Happens to Symptoms When You Stop

Vasomotor symptoms return in a significant proportion of women after discontinuing combination hormone therapy, regardless of age. The NAMS 2015 position statement on hormone therapy notes that roughly 50 percent of women experience symptom recurrence within weeks of discontinuation. In women who have been on therapy for 10 or more years, the return can be abrupt and severe, which is why gradual tapering over 3 to 6 months is preferred over stopping cold.

Non-hormonal options with evidence for vasomotor symptom management in women 65 and older include paroxetine 7.5 mg (the only FDA-approved non-hormonal option for this indication), escitalopram, venlafaxine, and gabapentin. Fezolinetant, a neurokinin 3 receptor antagonist, received FDA approval in 2023 specifically for moderate-to-severe vasomotor symptoms and is an option without the hormonal risks, though data in women 65 and older as a subgroup are limited.